Not medical advice. Talk to your provider before using any peptide. Full disclaimer
Semax vs Selank
Peptide Schedule Research TeamReviewed Apr 7, 20268 Citations
Semax and Selank are both seven-amino-acid peptides from Russian labs, usually taken as nasal drops. Semax is built on a fragment of ACTH and is studied for memory, BDNF and stroke recovery. Selank is studied for anxiety. Almost all of the evidence on both comes from Russian research groups.
226 PubMed citations and a prescription approval in Russia. That track record separates Semax (Met-Glu-His-Phe-Pro-Gly-Pro, ACTH 4-10 analog) from most peptides in the nootropic category. The mechanism is centered on BDNF. Dolotov and colleagues confirmed that a single Semax dose at 50 mcg/kg produced a 3-fold increase in BDNF mRNA and a 1.4-fold increase in BDNF protein in the rat hippocampus (PMID 16996037). A separate group showed binding-specific increases in BDNF protein in the basal forebrain (PMID 16635254). Beyond neurotrophins, Semax activates dopaminergic and serotonergic systems without touching cortisol, unlike its parent molecule ACTH. In practice, the community doses 300 to 600 mcg intranasally each morning for 10 to 14 days. Thousands of user reports across r/Peptides, r/nootropics, and Longecity describe improved focus, verbal fluency, and working memory starting within the first few days. The Selank stack (300 mcg of each, intranasal AM) is the most popular combination, adding anxiolytic balance to the dopaminergic stimulation. Gusev and colleagues followed 110 stroke patients in Russia and found higher plasma BDNF in those given Semax courses. A 2025 study in transgenic Alzheimer's mice showed reduced amyloid plaques (PMID 41479572). Another 2025 paper in the British Journal of Pharmacology identified a new mu-opioid receptor mechanism for spinal cord injury recovery (PMID 40692165). The science is expanding, but it still leans heavily on animal models and small Russian clinical samples. No placebo-controlled RCT has been run in healthy adults at any dose.
View full guide →A 62-patient Russian study set this peptide against the benzodiazepine medazepam in generalized anxiety disorder and neurasthenia and found comparable anxiolytic effects (Zozulya et al. 2008, PMID 18454096). A second study, in 60 patients, set it against phenazepam and reported anxiety relief that lasted a week after the last dose (PMID 25176261). That level of clinical evidence puts Selank ahead of most research peptides. Selank (full sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide analog of tuftsin, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. Its mechanism hits multiple pathways at once. It inhibits enkephalinase, which extends the half-life of your body's own enkephalins. It modulates GABA receptor expression (confirmed at the gene level in PMID 26924987). And it influences serotonin pathways and BDNF levels. The practical result is an anxiolytic that doesn't sedate you or dull your thinking. Users across dozens of Reddit threads on r/peptides and r/Nootropics describe it as "taking the edge off" while leaving focus intact. The most common community protocol is 250 to 500 mcg daily for 2 to 4 weeks, then cycling off for an equal period. Intranasal delivery has become the community's preferred route for its faster onset (15 to 30 min) and convenience. Two honest caveats: every published clinical trial originates from Russian academic institutions, with no independent Western replication to date. And the plasma half-life is very short (roughly 2 to 3 minutes IV), which means the mechanism behind its prolonged effect still isn't fully explained. The FDA removed Selank acetate from the Category 2 bulks list in September 2024; it remains research-only in the US.
View full guide →At a Glance
| Attribute | ||
|---|---|---|
| Category | Cognitive | Cognitive |
| Safety Grade | B | B |
| Half-Life | ~2-3 min (IV) | ~2-3 min (IV) |
| Route | Subcutaneous or Nasal | Subcutaneous or Nasal |
| Vial Sizes | 5 mg | 5 mg |
| Beginner Dose | 200 mcg Daily | 250 mcg Daily |
| Moderate Dose | 500 mcg Daily | 500 mcg Daily |
| Aggressive Dose | 1 mg Daily | 750 mcg Daily |
| Dosing Source | Community | Community |
| Side Effects | Sleep disruption is the most consistently reported problem, and it is almost always a timing error. Semax increases dopamine turnover. Dosing after noon delays sleep onset for hours. Restricting administration to before 10 AM resolves the issue for most users. Even a 2 PM dose can wreck that night's sleep architecture. Anxiety and irritability rank second. The effect is dose-dependent. At 600 mcg per day and above, community reports of agitation, frustration with interruptions, and generalized anxiety increase sharply. Users with pre-existing anxiety disorders face the highest risk. Reducing the dose by 50% typically resolves the issue within 1 to 2 days. Stacking with Selank 300 mcg mitigates anxiety for most users; that combination is the most popular community protocol for exactly this reason. Nasal irritation affects intranasal users during the first week. Mild burning, tingling, and dryness at the mucosal surface are common and generally self-limiting. A saline rinse between doses helps. For persistent irritation, switching to subcutaneous injection eliminates the local effect entirely. Afternoon fatigue and a "comedown" feeling appear at doses of 600 mcg per day and higher. Splitting the dose into 2 administrations (morning and before 1 PM) or reducing to 300 to 400 mcg often solves this. Emotional blunting or mental flatness is reported with sustained use above 600 mcg per day beyond day 14. A minority of users running extended high-dose cycles also report reduced libido. Both effects resolve after stopping. Hair thinning has been described at very high doses over long periods. The reports are rare and uniformly described as reversible. Melanocortin receptor (MC4R) activation is the speculated mechanism. Human safety data is limited. The published literature comes from Russian clinical trials in stroke and cognitive disorder patients, not healthy adult nootropic users. No formal adverse event reporting exists for the community dosing context. Contraindications: pregnancy or breastfeeding (no safety data), known hypersensitivity to ACTH-derived peptides, active intracranial hypertension, history of seizure disorders (limited data, use with caution), and children under 18 without physician supervision. SSRIs and SNRIs require monitoring because Semax modulates serotonin systems; additive serotonergic effects are possible. Dopaminergic drugs (L-DOPA, dopamine agonists) carry additive stimulation risk; dose adjustment may be needed. Stop use and consult a physician if anxiety persists despite morning-only dosing at 300 mcg or below, if sleep disruption does not resolve with timing changes, or if blood pressure exceeds 130/80 mmHg. | The most important safety concern with Selank is its interaction profile, not the peptide itself. Selank modulates GABA receptor expression, serotonergic pathways, and enkephalin metabolism simultaneously. Combining it with benzodiazepines risks excessive CNS depression. Adding it to an SSRI or SNRI creates additive serotonergic activity; watch for agitation, tremor, and diaphoresis. If you're on immunosuppressive therapy (cyclosporine, tacrolimus, methotrexate), Selank's tuftsin-derived immunomodulatory effects may interfere with your intended immunosuppression. On its own, Selank looks mild in community reports, with little sedation. The medazepam study (PMID 18454096) and the phenazepam study (PMID 25176261) do not give adverse-event rates in their abstracts. No published study has measured dependence or withdrawal. What users actually report: the most common complaint is nasal stinging or irritation at higher intranasal doses (400 to 600 mcg per administration). Diluting with more bacteriostatic water or splitting the dose across both nostrils reduces this. Mild fatigue during the first one or two doses is occasionally mentioned but typically resolves quickly. Batch-to-batch inconsistency in unregulated research-grade products is the number one cause of "non-response" in community reports; that's a quality problem, not a pharmacological one. The effect is too subtle for acute panic. Selank is a background anxiolytic, not a rescue medication. If you're expecting benzodiazepine-level sedation on demand, you'll be disappointed. By design, the effect ceiling is lower. All published clinical data comes from Russian institutions. Total human trial exposure is limited to the study populations described above. No long-term safety data beyond trial durations (typically 2 to 4 weeks) exists. Pregnancy and breastfeeding are absolute contraindications due to insufficient safety data. Children under 18 have not been studied. Active autoimmune conditions may be affected by Selank's immunomodulatory properties. Practical stop signals: discontinue if you experience paradoxical anxiety increase, any hypersensitivity reaction (rash, itching), or signs of excessive serotonergic activity when combined with other medications. Consult a physician before combining Selank with any CNS-active medication. |
Key Differences
Semax's best-known effect is on BDNF, a growth factor for brain cells. In rats, one dose (50 mcg/kg) raised hippocampal BDNF protein 1.4-fold and activation of its receptor, trkB, 1.6-fold [1]. Treated rats also made more correct responses in an avoidance learning test.
Selank's research points to GABA, the system benzodiazepines act on. In rats, Selank and GABA shifted many of the same neurotransmission genes in the frontal cortex within an hour [2]. The authors name allosteric modulation of GABA signaling as one possible mechanism.
Semax's human data is Russian clinical work. In 110 patients recovering from ischemic stroke, those given Semax courses had higher plasma BDNF and better Barthel scores for daily function [3]. The paper is in Russian, and its abstract describes Semax and no-Semax subgroups rather than a placebo-controlled trial.
Selank's human data is Russian too. In 62 patients with generalized anxiety disorder or neurasthenia, Selank and the benzodiazepine medazepam eased anxiety about equally [4]. Selank also showed antiasthenic and stimulant effects in that study.
A second Russian study set Selank against phenazepam in 60 patients with anxiety and somatoform disorders. It reported a clear anxiolytic effect, mild nootropic effects, and relief that lasted a week after the last dose [5]. Neither Selank study reports a placebo arm in its abstract.
Both have small brain-imaging studies in healthy volunteers. With 14 people on Semax and 10 on placebo, intranasal Semax enlarged the rostral part of the resting default mode network within 20 minutes [6]. A later fMRI study compared Semax, Selank and placebo and found shared and distinct effects on amygdala connectivity [7].
Community reports describe Semax as the focus peptide and Selank as the calm one. That split follows the research direction, but no trial has compared the two on anxiety or memory.
When to Choose Semax
When to Choose Selank
Anxiety is the main concern (Russian studies against medazepam and phenazepam)
Calm without sedation matters most (community reports)
Stress-related fatigue or neurasthenia is part of the picture [4]
Verdict
Science and community line up on this pair. Semax's evidence centers on BDNF in rats and stroke recovery in Russian patients. Selank's centers on anxiety, with two Russian studies against benzodiazepines. Both evidence bases are small, mostly from one country, and light on placebo controls. Community reports use Semax for focus and Selank for calm, and many run both.
Research peptides with both sides of the evidence.
Published studies and community reports, side by side, for 150+ peptides. Save the ones you are weighing and see when anything changes.
Can You Stack Semax + Selank?
Community reports often pair them, Semax for focus and Selank to keep anxiety down. No trial has tested the combination. In the research above they act on different systems (BDNF for Semax, GABA-linked genes for Selank).
Dosage Calculators
Or use the universal Peptide Calculator for any peptide.
Related Guides & Stacks
Peptide Schedule Research TeamReviewed Apr 8, 20268 Citations
References
- [1]Semax regulates BDNF and trkB expression in the rat hippocampus (Dolotov et al., Brain Res 2006) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [2]Selank and the expression of GABAergic neurotransmission genes in rat frontal cortex (Volkova et al., Front Pharmacol 2016) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [3]Semax and rehabilitation timing after ischemic stroke, 110 patients, in Russian (Gusev et al., Zh Nevrol Psikhiatr 2018) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [4]Selank vs medazepam in 62 patients with generalized anxiety disorder or neurasthenia, in Russian (Zozulia et al., 2008) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [5]Selank vs phenazepam in 60 patients with anxiety and somatoform disorders, in Russian (Medvedev et al., 2014) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [6]Intranasal Semax and the default mode network on resting-state fMRI in 24 healthy volunteers (Lebedeva et al., 2018) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [7]Selank, Semax and placebo on resting-state functional connectivity of the amygdala (Panikratova et al., Dokl Biol Sci 2020) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [8]Selank after intranasal and intraperitoneal dosing in BALB/c and C57BL/6 mice, in Russian (Eksp Klin Farmakol 2016) (opens in a new tab)PubMed (opens in a new tab)PubMed